Specifically for VEGFR TKIs, the results of axitinib regarding hypertension and bleeding align with those from previous reports; cediranib aligns with prior findings on hypertension but not bleeding in this study (Abdel-Rahman and Fouad, 2014). Here, KDR is linked to hypertensive disorder.